Obesity Medicine 2025 - Muscle Safety: Addressing GLP-1 Agonist Concerns with Exercise & Nutrition (Recorded)
The rise in the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) for weight loss has generated significant interest due to their efficacy in reducing body weight. However, this trend has also highlighted a critical health concern: the unintended loss of muscle mass. While these therapies effectively shed excess pounds, they also contribute to a decrease in muscle mass, raising concerns about the potential long-term impact on overall health. This is of particular concern for individuals already at risk for age-related impairments in muscle mass and function, such as middle-aged and older adults. This session is important for filling current practice and knowledge gaps, providing clinicians with strategies to optimize patient outcomes in the context of GLP-1RA therapy. It is structured to be both informative and interactive, incorporating visuals, thought-provoking questions, and problem-solving exercises and to equip attendees with the tools and knowledge necessary to optimize GLP-1RA therapies in their daily clinical practice, ultimately leading to better patient outcomes.
CME/CE Expiration Date: 4/27/28
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Christos S. Katsanos, PhD
Associate Professor
Arizona State University and Mayo Clinic Arizona
Available Credit
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.